Trial reportBMJ open2025
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China.
Trial report in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03866993 (A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer
Who cites it
1 citing paper in PubMed.
- Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPenpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). However, the cost-effectiveness of this treatment in China remains to be determined. In this study, we aimed to assess the cost-effectiveness of penpulimab combined with paclitaxel and carboplatin for metastatic sq-NSCLC.
designBased on the AK105-302 trial (NCT03866993), a Markov model was created to evaluate the disease progression of metastatic sq-NSCLC patients over 10 years. The model included progression-free survival, progressive disease and death. The utility values were derived from published literature. Sensitivity studies were used to assess the robustness of the model outputs.
settingThe Chinese healthcare system perspective.
participantsA hypothetical Chinese cohort of patients with locally advanced or metastatic sq-NSCLC.
interventionsPenpulimab plus chemotherapy versus chemotherapy. PRIMARY OUTCOME MEASURE: Costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER).
resultsCompared with the chemotherapy alone group, the cost of penpulimab plus chemotherapy increased by US$3717.72, with an increase of 0.43 QALYs. The ICER was US$8625.78/QALY, which was well below the willingness-to-pay threshold of US$38 052/QALY. This demonstrated higher cost-effectiveness benefits, as confirmed by the sensitivity analysis results.
conclusionsUnder the Chinese health system, penpulimab plus paclitaxel and carboplatin is cost-effective for metastatic sq-NSCLC patients and can be used as an economical and effective treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.